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ttp://dx.doi.org/10.1016/j.ajpath.2014.03.013Epithelial-mesenchymal transition (EMT) is associated with ﬁbrotic diseases in the lens, such as anterior
subcapsular cataract (ASC) formation. Often mediated by transforming growth factor (TGF)-b, EMT in the
lens involves the transformation of lens epithelial cells into a multilayering of myoﬁbroblasts, which
manifest as plaques beneath the lens capsule. TGF-beinduced EMT and ASC have been associated with the
up-regulation of two matrix metalloproteinases (MMPs): MMP-2 and MMP-9. The current study used
MMP-2 and MMP-9 knockout (KO) mice to further determine their unique roles in TGF-beinduced ASC
formation. Adenoviral injection of active TGF-b1 into the anterior chamber of all wild-type and MMP-2 KO
mice led to the formation of distinct ASC plaques that were positive for a-smooth muscle actin, a marker
of EMT. In contrast, only a small proportion of the MMP-9 KO eyes injected with adenovirus-expressing
TGF-b1 exhibited ASC plaques. Isolated lens epithelial explants from wild-type and MMP-2 KO mice that
were treated with TGF-b exhibited features indicative of EMT, whereas those from MMP-9 KO mice did not
acquire a mesenchymal phenotype. MMP-9 KO mice were further bred onto a TGF-b1 transgenic mouse line
that exhibits severe ASC formation, but shows a resistance to ASC formation in the absence of MMP-9.
These ﬁndings suggest that MMP-9 expression is more critical than MMP-2 in mediating TGF-beinduced
ASC formation. (Am J Pathol 2014, 184: 2001e2012; http://dx.doi.org/10.1016/j.ajpath.2014.03.013)Supported by the NIH grant R01-017146-06 (J.W.M.) and the Natural
Sciences and Engineering Research Council 20/20 Network (H.S.).
Disclosures: None declared.A cataract is an opacity that forms in the lens and is charac-
terized by an increase in light scatter and a loss of lens trans-
parency. Cataract is the leading cause of blindness worldwide
despite the availability of effective surgery in developed
countries.1,2 According to the World Health Organization, up
to 39 million people are blind worldwide, and of these, 51% of
them are blind because of cataract; 65% of blind people are
older than 50 years.2,3 Treatment involves surgical removal of
the cataractous lens, replacing it with a synthetic intraocular
lens. Although this offers quick restoration of vision, it is the
most frequently performed surgical procedure in the devel-
oped world, with approximately 3 million operations per-
formed in the United States per year,4 carrying a cost of $3.4
billion.5 Cataract surgery can also lead to a number of com-
plications, the most common of which is secondary cataract,
also known as, posterior capsular opaciﬁcation (PCO).6e10
PCO is considered to be a proliferative ﬁbrotic disorder that
is characterized by aberrant extracellular matrix (ECM)
deposition andwrinkling of the posterior lens capsule. Another
related type of ﬁbrotic cataract is anterior subcapsular cataract
(ASC). ASC is a primary cataract that develops after astigative Pathology.
.pathologic insult, such as ocular trauma or surgery, or sys-
temically, as with diseases such as atopic dermatitis and reti-
nitis pigmentosa. In ASC, the monolayer of epithelial cells on
the anterior surface of the lens [lens epithelial cells (LECs)] is
triggered to proliferate and transform into large spindle-shaped
cells, or myoﬁbroblasts, through a phenomenon known as
epithelial-mesenchymal transition (EMT).11e13 These myoﬁ-
broblasts form ﬁbrotic plaques beneath the anterior lens
capsule and express contractile elements, such as a-smooth
muscle actin (a-SMA). Similar to ASC, during PCO, a pro-
portion of LECs, which remain within the capsule after cata-
ract surgery, are triggered to proliferate and migrate to the
posterior lens capsule, where they undergo EMT into myoﬁ-
broblasts and contribute to capsular wrinkling and aberrant
matrix deposition.7,11,13 Recent evidence has suggested that
the matrix metalloproteinases (MMPs), enzymes involved in
Korol et alremodeling the ECM, play an important role in the develop-
ment of both of these ﬁbrotic cataract phenotypes.
MMPs are a family of >25 genetically distinct but struc-
turally related zinc-dependent matrix degrading enzymes
that participate in many physiologic processes, including
embryogenesis and wound healing, and are implicated in
ﬁbrosis and a number of diseases.14e16 Although they are
principally known for their role in ECM remodeling, addi-
tional roles for MMPs have recently emerged, including their
ability to regulate cell migration, invasion, and cell signaling,
as well as EMT in multiple tissues.17,18 Accumulating studies
have demonstrated that the expression of speciﬁc MMPs is
induced in a variety of cataract phenotypes, including ASC
and PCO,16 as well as others, such as posterior subcapsular
cataracts.19 Furthermore, inhibition of MMP activity through
the use of broad MMP inhibitors, such as GM6001 or EDTA,
and speciﬁc MMP inhibitors have been reported to suppress
cellular features known to contribute to ASC and PCO, such
as lens epithelial cell migration, EMT, and capsular bag
contraction.16,20,21
In particular, the gelatinases, MMP-2 and MMP-9, have
been implicated in ASC and PCO, and a signiﬁcant induction
in their secretion was found to occur in a rodent model
of ASC after treatment with transforming growth factor
(TGF)-b.22,23 TGF-b has been reported to play a pivotal role
in ASC and PCO. In the anterior chamber of the eye, latent
TGF-b is a normal constituent of the aqueous humor, which
bathes and nourishes the lens.24 Activation of TGF-b ligands,
after injury, results in the recruitment of an active TGF-b
receptor tetramer capable of signal transduction, which ini-
tiates EMT. Indeed, a number of in vitro and in vivo models
have found that addition of active TGF-b1 or TGF-b2 induces
EMT in the lens and results in ASC formation, which closely
mimics human ASC.23,25e27 Using the excised rat lens model
of ASC, our laboratory has found that co-treatment of lenses
with active TGF-b and either of two commercially available
MMP inhibitors, GM6001, a broad MMP inhibitor, or a
MMP-2/9especiﬁc inhibitor, signiﬁcantly suppressed both
EMT and subsequent ASC formation.23 These data demon-
strated, for the ﬁrst time to our knowledge, that inhibition of
these speciﬁc MMPs could block ASC formation in a whole
(excised) lens and further indicate the requirement for MMP-2
and MMP-9 in the EMT of LECs.
MMP-2 and MMP-9 are closely related MMPs that
degrade basement membrane components and are consid-
ered to have some redundant and cooperative roles during
development and disease. For example, in MMP-2/MMP-9
double knockout (KO) mice both the incidence and the
severity of choroidal neovascularization (which leads to
age-related macular degeneration) were strongly attenuated
compared with single-gene deﬁcient mice or corresponding
wild-type controls.28 Additional studies in the lens revealed
that during ASC formation MMP-9 mRNA is induced
before MMP-2, and the addition of recombinant human
MMP-9 to a human lens epithelial cell line, FHL-124, is
able to induce MMP-2, along with the EMT marker2002a-SMA.22 Together these ﬁndings suggest that, of the two
gelatinases, MMP-9 may play a more critical role in ASC
formation. The unique roles that these MMPs play in ASC
formation, however, have yet to be tested.
In the current study, we addressed the individual re-
quirement(s) of MMP-2 andMMP-9 in ASC formation using
two models of lens-speciﬁc TGF-b overexpression. Adeno-
viral delivery of TGF-b1 to the anterior chamber of the eye of
MMP-2 and MMP-9 KO mice revealed that, although wild-
type and MMP-2 KO mice formed distinct ASC plaques,
virtually all of theMMP-9 KO eyes injected with adenovirus-
expressing TGF-b1 (AdTGF-b1) did not. To further delin-
eate a role for MMP-9 in ASC formation, MMP-9 KO mice
were also bred onto a TGF-b1 transgenic, gain-of-function
line that exhibits severe ASC formation. The MMP-9 KO
mice also had substantial resistance to ASC formation in this
model. Finally, lens epithelial explants isolated fromMMP-2
and MMP-9 KO mice further demonstrated that, although
wild-type and MMP-2 KO explants treated with TGF-b
exhibited a loss in epithelial cell characteristics, MMP-9 KO
explants did not. Overall, these ﬁndings suggest that of the
two MMPs, MMP-9 expression is more critical in TGF-
beinduced EMT and ASC formation.
Materials and Methods
Animal Studies
All animal studies were performed according to the Cana-
dian Council on Animal Care Guidelines and the Associa-
tion for Research in Vision and Ophthalmology Statement
for the Use of Animals in Ophthalmic and Vision Research.
MMP-2 KO mice (Baylor College of Medicine, Houston,
TX),29 and MMP-9 KO mice (Jackson Laboratories, Bar
Harbor, ME) were on a C57BL/6 background and were
generated by the removal of exon 1 of the Mmp2 gene and
removal of part of exon 2 and all of intron 2 of the Mmp9
gene. In both cases, these regions were replaced with a
pgk-neo gene cassette.30,31 TGF-b1 transgenic mice were
obtained from Dr. Paul Overbeek (Baylor College of
Medicine) and contain a porcine TGF-b1 cDNA construct
with an aA-crystallin promoter designed for lens-speciﬁc
expression of active TGF-b1 on a FVB/N/C57BL/6J
genetic background.32 TGF-b transgenics were crossed with
MMP-9 KO animals to generate TGF-bþ/MMP-9þ/ mice.
The experimental animals were then created by breeding
TGF-bþ/MMP-9þ/ with TGF-b/MMP-9þ/. Wild-type
littermates were used to account for the various differ-
ences among the strains of mice.
Genotype Analysis
DNA extraction and puriﬁcation from mouse ear tissue were
performed with a kit (DNeasy; Qiagen, Inc., Toronto, ON,
Canada). Genotypes were determined by PCR analysis.
Mmp2 andMmp9wild-type andKO alleleswere detected usingajp.amjpathol.org - The American Journal of Pathology
TGF-beInduced ASC-Resistant Micethe following primers. The Mmp2 wild-type allele was
detected by using primers 50-CAACGATGGAGGCACGAG-
TG-30 (forward) and 50-GCCGGGGAACTTGATGATGG-30
(reverse) amplifying a 120-bp fragment. The Mmp2 KO allele
was detected by using primers 50-TGTATGTGATCTGGTT-
CTTG-30 (forward) and 50-TGCAAAGCGCATGCTCCA-
GA-30 (reverse) to yield a 1.1-kbp fragment. PCR reactions
were performed for 35 cycles in the following conditions: initial
heating for 2 minutes at 94.5C, denaturation for 1 minute at
94.5C, annealing for 1 minute at 57C, and extension for 1.5
minutes at 72C. A ﬁnal extension was performed for 5minutes
at 72C. The Mmp9 wild-type allele was detected by using
primers 50-GTGGGACCATCATAACATCAC-30 (forward)
and 50-CTCGCGGCAAGTCTTCAGAGTA-30 (reverse)
amplifying a 277-bp fragment. The Mmp9 KO allele was
detected by using primers 50-CTGAATGAACTGCAGGC-
AGA-30 (forward) and 50-ATACTTCTCGGCAGGAGCA-30
(reverse) to yield a 172-bp fragment. PCR reactions were per-
formed for 35 cycles in the following conditions: initial heating
for 2 minutes at 94C, denaturation for 30 seconds at 94C,
annealing for 30 seconds at 60C, and extension for 2 minutes
at 72C. A ﬁnal extension was performed for 10 minutes at
72C. The TGF-b1 transgene was identiﬁed using primers
speciﬁc for the simian virus 40 sequences in the transgene.
The sense primer (50-GTGAAGGAACCTTACTTCTGTGG-
TG-30) and the antisense primer (50-GTCCTTGGGGTCTTCT-
ACCTTTCTC-30) yield a 300-bp fragment. PCR reactions
were performed for 36 cycles using the following conditions:
initial heating for 3 minutes at 94C, denaturation for 30 sec-
onds at 94C, annealing for 1 minute at 57C, and extension for
1 minute at 72C. A ﬁnal extension was performed for 10 mi-
nutes at 72C. Agarose gel electrophoresis (1.5% agarose) with
ethidium bromide detection was used to visualize the PCR re-
action products.
Recombinant Adenovirus
Biologically active porcine TGF-b1 was administered into
the anterior chamber of mouse eyes in these studies using a
previously validated adenoviral gene transfer method.33 To
produce constitutively and biologically active TGF-b1
protein, TGF-b cDNA was mutated with two cysteine to
serine point mutations at sites 223 and 225 (TGF-b223/225)
located in the pro region of precursor TGF-b,34 preventing
the resulting protein from binding to its latency-associated
protein. This mutated cDNA was used to construct a re-
combinant, replication-deﬁcient type 5 adenovirus, where
the E1 region was replaced by the human cytomegalovirus
promoter, driving the expression of TGF-b223/225 followed
by the simian virus 40 polyadenylation signal.35 The
resultant adenovirus (AdTGF-b) was ampliﬁed in 293 cells,
puriﬁed by cesium chloride gradient centrifugation and
concentrated using a Sephadex PD-10 chromatography
column (Sigma-Aldrich Co., St. Louis, MO). An empty
control adenoviral-delete vector (AdDL), with no insert in
the deleted E1 region, was produced by similar methods.35The American Journal of Pathology - ajp.amjpathol.orgAdenoviral vectors were intracamerally injected into
MMP-2 and MMP-9 wild-type and KO mice, as described
previously.36,37 All animal procedures were performed with
the animals under inhalation anesthesia with isoﬂurane
(MTC Pharmaceuticals, Cambridge, ON, Canada). AdTGF-b
or AdDL at 5  108 PFU were injected in a volume of 5 mL
in PBS. Brieﬂy, mice were anesthetized with isoﬂurane and
placed under a dissecting microscope to visualize general
eye structures. Virus solution (5 mL) was administered into
the anterior chamber of each mouse using a 33-gauge needle
attached to a 10-mL Hamilton syringe. Eyes were covered
with ophthalmic lubricating ointment (Lacrilube; Allergen,
Irvine, CA) after injection, and animals were allowed to
recover before returning to their cages. Animals were
sacriﬁced 2 to 3 weeks after injection.
Ex Vivo Mouse Lens Epithelium Explants Preparation
and Treatment
To obtain lens epithelial cell explants, 6- to 8-week-old
MMP-2 and MMP-9 wild-type and KO mouse lenses were
dissected and placed in 35-mm basement cell extractecoated
(Trevigen, Inc., Gaithersburg, MD) culture plates that con-
tained prewarmed, serum-free medium M199, supplemented
with antibiotics (Invitrogen, Inc., Burlington, ON, Canada).
The lens was placed posterior side up, the posterior pole was
gently torn, and the ﬁber mass was slowly removed,
revealing the epithelium. Once separated, the epithelium is
then pinned with a blunt tool to the bottom of the culture dish,
with the LECs directly bathed by the medium and the outer
lens capsule facing downward. Twenty-four hours after
explanting, conﬂuent mouse epithelial explants were left
untreated in serum-free M199 or treated with TGF-b2 (R&D
Systems, Inc., Minneapolis, MN) at 500 pg/mL for 48 hours.
Histologic Analysis and Immunoﬂuorescence
AdTGF-be or AdDL-injected (2 to 3 weeks after injection)
or transgenic (1 to 3 months of age) mice were sacriﬁced
and enucleated. Eyes were processed overnight in 10%
neutral buffered formalin, dehydrated, embedded in
parafﬁn, and processed for routine histologic analysis.
Midsagittal sections (4 mm) were stained with H&E or for
immunohistochemical (IHC) detection of a-SMA. For
a-SMA detection, parafﬁn sections were deparafﬁnized,
rehydrated, and incubated with 5% normal goat serum for
20 minutes at room temperature. Sections were incubated
with mouse antiea-SMA monoclonal antibody conjugated
to ﬂuorescein isothiocyanate (1:100; Sigma-Aldrich Co.,
Oakville, ON, Canada) at room temperature for 1 hour. All
sections were mounted in Prolong Gold antifade reagent
with DAPI (Invitrogen, Inc., Eugene, OR) to visualize the
nucleus. Staining was visualized with a Leica DMRA2
ﬂuorescence microscope (Leica Microsystems Canada, Inc.,
Richmond Hill, ON, Canada) equipped with a Q-Imaging
RETIGA 1300i FAST digital camera (Q-Imaging, Surrey,2003
Korol et alBC, Canada). Images were captured using OpenLab soft-
ware version 4.0 (PerkinElmer LAS, Shelton, CT). Images
were reproduced for publication (Photoshop CS3; Adobe
Systems, Inc., Mountain View, CA).
After 48 hours, untreated and treated mouse lens explants
were ﬁxed for 15 minutes with 10% neutral buffered formalin,
then incubated at room temperature with the permeabilizer
(0.1% Triton X-100 in 0.5% SDS) and 5% donkey serum for 1
hour. Staining was performed overnight at 4C with explants
detached from the culture dish and left free-ﬂoating in a glass
tube, with an antiea-SMA ﬂuorescein isothiocyanate con-
jugated monoclonal antibody (1:200; Sigma-Aldrich Co.,
Oakville, ON, Canada), antieE-cadherin mouse monoclonal
antibody (1:200; BD Transduction Laboratories, Mississauga,
ON, Canada), and antiactive b-catenin (clone 8E7; EMD Mil-
lipore Corp, Temecula, CA). E-cadherin was visualized using a
donkey anti-mouse secondary antibody (1:200; Invitrogen,
Inc.). After antibody incubation, the explants were washed
repeatedly with PBS and mounted in Prolong Gold antifade
reagent with DAPI. Levels of a-SMA in stained explants were
quantiﬁed using ImageJ quantiﬁcation software version 1.44
(NIH, Bethesda,MD). Fluorescencewas normalized to number
of cells in each image and compared with control levels.
Western Blot Analysis
Lens epithelial explants isolated from MMP-9 wild-type and
KO mice were collected for Western blot analysis of
E-cadherin, as described previously.38 Five LEC explantsFigure 1 Effects of adenoviral gene transfer of active TGF-b1 after 2 to 3 w
stained with H&E (AeD) or subjected to immunostaining for a-SMA (EeH, green).
KO (B; nZ 6) mice treated with AdTGF-b and in both cases is associated with indu
a monolayer of LECs (C; nZ 10) that did not express a-SMA (G), resembling mous
intact lens capsule in all lenses after adenoviral injection. All sections were mount
A and D are artifacts. c, cornea; i, iris; le, lens epithelium. Scale bar Z 100 mm
2004per sample were homogenized in Triton-X 100 lysis buffer
that contained protease inhibitor cocktail (Roche Applied
Science, Laval, QC, Canada). Total protein concentration of
the lysates was determined using Bradford protein assay
(Bio-Rad Laboratories, Mississauga, ON, Canada).
Equal amounts of total protein were loaded in 10%
SDS-polyacrylamide gels. The resolved bands were elec-
trotransferred onto a nitrocellulose membrane (Pall Corpo-
ration, East Hills, NY). Membranes were blocked with
Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln,
NE) and incubated at room temperature for 1 hour and then
incubated overnight at 4C with a mouse antieE-cadherin
antibody (1:8000) and chicken polyclonal antieb-tubulin III
(1:8000; Abcam, Inc., Toronto, ON, Canada). After the
overnight incubation, membranes were washed repeatedly
in PBS and probed with corresponding LI-COR IRDye
secondary antibodies (1:10,000, LI-COR Biosciences).
Blots were visualized using the LI-COR Odyssey imaging
system, and densitometric analysis was performed using
ImageJ quantiﬁcation software.
E-Cadherin ELISA
Levels of E-cadherin were measured in the culture media of
untreated and treated wild-type and MMP-9 KO LEC ex-
plants by using a mouse E-cadherinespeciﬁc enzyme-linked
immunosorbent assay (ELISA; R&D Systems, Inc., Min-
neapolis, MN). Media from explant dishes (four to six ex-
plants per dish) was collected and concentrated. Standardseeks. Histologic sections from mice injected with AdTGF-b1 or AdDL were
Focal multilayering of LECs occurs in both wild-type (A; nZ 7) and MMP-2
ction of a-SMA (E and F). MMP-9 KO mice treated with AdTGF-b maintained
e eyes injected with AdDL control vector (D and H). Note the presence of an
ed in medium with DAPI to co-localize the nuclei (blue). The small circles in
(AeH).
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Figure 2 Effects of TGF-b on E-cadherin localization and a-SMA levels
in wild-type mouse LEC explants. Conﬂuent LEC explants when left un-
treated (AeC; nZ 9) maintain a tightly packed, cuboidal, cobblestone-like
appearance in a monolayer with E-cadherin expressed at cellular junctions
(A) and negligible a-SMA expression (B, green). Mouse LECs treated with
500 pg/mL of TGF-b for 48 hours (DeF; n Z 10) exhibit a distinct loss of
E-cadherin (D) and marked expression of a-SMA (E). G: TGF-b leads to a
signiﬁcant induction in a-SMA compared with untreated wild-type lens
explants. All explants were mounted in medium with DAPI to co-localize the
nuclei (C and F, blue). Scale bar Z 100 mm (AeF). Data are expressed as
means  SEM. *P < 0.05.
TGF-beInduced ASC-Resistant Miceand samples were applied to a microplate coated with rat
anti-mouse E-cadherin recognizing the N-terminal domain
of E-cadherin, and the assay was performed according to the
manufacturer protocol. The optical density of standards and
samples was determined at 450 nm using a microplate
reader, and E-cadherin protein concentrations were extrap-
olated from a standard curve.
Statistical Analysis
Data are expressed as means  SEM and were tested for
signiﬁcance by Student’s t-test or one-way analysis of
variance where appropriate (SPSS statistical software
version 22.0; SPSS, Inc., Chicago, IL). Tukey post hoc
comparisons were performed when statistical signiﬁcance
(P < 0.05) was found among the observations.
Results
Delivery of AdTGF-b1 to the Anterior Chamber Results
in ASC Formation in MMP-2 KO Mice But Not MMP-9 KO
Mice
AdTGF-b injections for the delivery of genes into the lens
have been previously validated by our laboratory37 through theThe American Journal of Pathology - ajp.amjpathol.orginjection of the reporter constructs adenoviral-LacZ and
adenoviral-GFP into the anterior chamber of mouse eyes.
Transgene expression was detected in the lens epithelium 4
days after injection in the absence of a capsular break, whereas
transgene expression was absent in the lens epithelium of the
AdDL injected eyes. In the current study, we used this
approach with MMP-2 and MMP-9 KO mice and their wild-
type littermates. One eye of each mouse was injected with
AdTGF-b1, and the contralateral eye served as an uninjected
control. Eyes from additional mice were also injected with
AdDL vectors, which served as a control vector with no insert
within the deleted E1 region. Two weeks after injection 100%
of all wild-typemice treated with AdTGF-b1 exhibited distinct
ASC plaques that consisted of a focal multilayering of LECs
beneath the intact anterior lens capsule (Figure 1A). Each of
the AdTGF-b1etreated eyes commonly exhibited one plaque,
typically found in a central location of the anterior region of the
lens. AdDL vectors did not induce any ASC features after
injection into the wild-type eyes (Figure 1D). Similar to their
wild-type littermates, all of the MMP-2 KOmice injected with
AdTGF-b1 exhibited ASC formation (Figure 1B). The ASC
plaques in the MMP-2 KOs were also comparable in size and
location to their wild-type controls. Importantly, in contrast to
both wild-type and MMP-2 KO eyes, delivery of active
AdTGF-b1 to the anterior eye chamber of MMP-9 KO mice2005
Figure 3 Effects of TGF-b treatment on E-cadherin localization and
a-SMA levels in MMP-2 KO mouse lens epithelial explants. MMP-2 KO
explanted LECs, when left untreated (AeC; nZ 10), maintained a cuboidal
arrangement with E-cadherin staining present at intact cellular junctions
(A) and negligible a-SMA expression (B, green) similar to wild-type LECs. In
the absence of MMP-2, 500 pg/mL of TGF-b treatment for 48 hours (DeF;
n Z 7) induced a phenotypic transformation with a distinct loss of
E-cadherin (D) and marked expression of a-SMA (E), similar to treated wild-
type LECs. G: TGF-b leads to a signiﬁcant induction in a-SMA compared with
untreated MMP-2 KO lens explants. All explants were mounted in medium
with DAPI to co-localize the nuclei (C and F, blue). Scale bar Z 100 mm
(AeF). Data are expressed as means  SEM. *P < 0.05.
Korol et alresulted in signiﬁcant resistance to ASC formation
(Figure 1C). Of the 11 treated eyes examined, only one
exhibited a small focal plaque, whereas the remaining
lenses had a normal epithelial monolayer, similar to that
observed in untreated eyes.
To conﬁrm that the subcapsular plaques observed in the
AdTGF-b1etreated eyes consisted of myoﬁbroblasts, as
previously reported in human ASC and other animal models
of ASC, lens sections were prepared from postinjected eyes
and subjected to immunostaining for a-SMA. In the
AdTGF-b1etreated wild-type eyes, distinct expression of
a-SMA was observed in a substantial proportion of cells
within the plaques (Figure 1E). This was also the case for
the MMP-2 KO mice injected with AdTGF-b1 (Figure 1F).
In comparison, the undisrupted lens epithelial monolayer of
the MMP-9 KO mice failed to stain positive for the myo-
ﬁbroblast cell marker, a-SMA (Figure 1G), resembling
control eyes (Figure 1H).
Alteration in Markers of EMT in LECs Requires MMP-9
But Not MMP-2
The dissolution of cell-cell contacts, notably loss of E-
cadherin from epithelial cells, is a key characteristic in the
transition of an epithelial cell to a mesenchymal cell.2006Therefore, to directly examine the effect of TGF-b on the
dissolution of E-cadherin in MMP-2 and MMP-9 KO mice
and their wild-type littermates, explant cultures were used.
Isolating and explanting of the lens epithelium is an effec-
tive ex vivo model that is well suited for studying the
mechanisms behind the transformation of these epithelial
cells into a mesenchymal phenotype. Untreated wild-type
explant LECs (Figure 2, AeC) exhibited the characteristic
epithelial cell phenotype with clear E-cadherin staining at
the cell borders and junctions (Figure 2A) accompanied by
little to no a-SMA expression (Figure 2B). When wild-type
explant cells were treated with 500 pg/mL TGF-b for 48
hours (Figure 2, DeF), their morphologic features drasti-
cally changed, including a distinct loss of E-cadherin
expression at the cell junctions (Figure 2D) and an increase
in a-SMA expression (Figure 2E), indicating that TGF-b
had induced their transformation into contractile myoﬁbro-
blasts. The increase in a-SMA in TGF-betreated explants
was signiﬁcant (34.5  12.5) relative to untreated controls
(Figure 2G) (P Z 0.022). In comparison, LEC explants
from MMP-2 KO lenses, when left untreated, also main-
tained a cuboidal arrangement with intact cell junctions
expressing E-cadherin and no observable a-SMA (Figure 3,
AeC). Notably, in the MMP-2 KO explants, TGF-b was
still able to induce a phenotypic transformation in theajp.amjpathol.org - The American Journal of Pathology
Figure 4 Effects of TGF-b treatment on E-cadherin localization and
a-SMA levels in MMP-9 KO mouse lens epithelial explants. MMP-9 KO LEC
explants when left untreated (AeC; nZ 9) exhibited irregular E-cadherin
staining (A) with negligible a-SMA expression (B, green). LECs treated
with 500 pg/mL of TGF-b for 48 hours in the absence of MMP-9 (DeF;
nZ 5) maintained a similar E-cadherin proﬁle as the untreated controls
(D) and, in contrast to TGF-betreated wild-type and MMP-2 KO explants,
did not express a-SMA (E). G: TGF-b did not signiﬁcantly induce a-SMA
expression when compared with untreated MMP-9 KO lens explants. All
explants were mounted in medium with DAPI to co-localize the nuclei
(C and F, blue). Scale bar Z 100 mm (AeF). Data are expressed as
means  SEM.
TGF-beInduced ASC-Resistant Miceepithelial cell monolayer with a clear loss of E-cadherin
(Figure 3D) and a signiﬁcant (11.9  3.5) increase in
expression of ﬁlamentous a-SMA (Figure 3, E and G)
(PZ 0.003) comparable to treated wild-type LEC explants.
These data substantiate the results from the AdTGF-b in-
jection experiments, suggesting that MMP-2 is not required
for TGF-bemediated EMT.
MMP-9 KO LEC explants, when left untreated, do not
resemble wild-type untreated explants (Figure 4, AeC). In
the absence of MMP-9 and without stimulation with TGF-b,
E-cadherin staining of cells was irregular and absent in some
cells (Figure 4A). This staining pattern remained the same
with TGF-b treatment (Figure 4D). In terms of myoﬁbro-
blast marker acquisition, untreated MMP-9 KO LECs
expressed no observable a-SMA (Figure 4B). Importantly,
MMP-9 KO LECs treated with TGF-b (Figure 4, DeF) did
not acquire a characteristic spindle-like mesenchymal
phenotype, and a-SMA expression (Figure 4E) did not
signiﬁcantly differ from MMP-9 KO untreated control cells
(Figure 4G). We also performed Western blot analyses to
determine the overall level of E-cadherin protein in MMP-9
KO LEC lysates compared with that of wild-type littermates
(Figure 5A). These experiments demonstrated that despite
the altered staining of E-cadherin in the MMP-9 KO ex-
plants, the levels of E-cadherin protein were notThe American Journal of Pathology - ajp.amjpathol.orgsigniﬁcantly different from those of wild-type mice
(Figure 5B). Because our earlier study using ex vivo rat
lenses revealed the appearance of a 72-kDa E-cadherin
fragment in the conditioned media of lenses treated with
TGF-b that was not detected in the media from untreated
lenses,23 we also assayed the conditioned media of the ex-
plants from wild-type and MMP-9 KO mice using an
ELISA speciﬁc for E-cadherin (Figure 5C). These experi-
ments revealed that unlike TGF-betreated wild-type ex-
plants that exhibited induced E-cadherin levels in the media
compared with untreated controls (P Z 0.074), the TGF-
betreated MMP-9 KO explants did not. In fact, the levels of
E-cadherin in the TGF-betreated MMP-9 KO media were
lower than all untreated explants and signiﬁcantly lower
than that of wild-type TGF-betreated explants (PZ 0.019).
Finally, to further investigate the resistance of the MMP-9
KO LEC explants to TGF-beinduced EMT, we used
another known marker of EMT, b-catenin. b-catenin is
important in linking E-cadherin to the cell cytoskeleton, and
its loss from the cell margins often precedes EMT in many
systems. Thus, activation of b-catenin, in which b-catenin
localization changes from a marginal localization pattern to
a more cytosolic and/or nuclear expression has been found
to occur in LEC explant cells after TGF-b treatment.39 Our
experiments found that wild-type explants treated with2007
Korol et alTGF-b exhibited predominantly cytosolic expression of
b-catenin (Figure 6, E and F) compared with untreated
controls (Figure 6, A and B), which exhibit a more marginal
staining that reﬂects the cobblestone packing of the cells.
Importantly, the MMP-9 KO explants treated with TGF-b
(Figure 6, G and H) resembled untreated controls with
marginal cell border staining (Figure 6, C and D). These
ﬁndings further conﬁrm the resistance of the MMP-9 KO
explants to TGF-beinduced EMT.
ASC Formation Is Suppressed When TGF-b Transgenic
Mice Are Bred onto the MMP-9 KO Background
To corroborate the AdTGF-b ﬁndings, we also assessed the
involvement of MMP-9 in a TGF-b1 lens-speciﬁc transgenic
model. This model involves the overexpression of self-
activating TGF-b1 driven by a lens-speciﬁc aA-crystallin
promoter.32 TGF-b1 transgenic mice develop one centrally
localized ﬁbrotic ASC beginning 3 weeks after birth. These
mice were crossed onto the MMP-9 null background to
obtain TGF-b1/MMP-9 KO mice. All transgenic mice that
were on theMMP-9 wild-type background (TGF-b1þ/MMP-
9þ/þ) developed focal multilayered opacities (Figure 7,
B and F). Interestingly, 75% of lenses derived from TGF-b1/
MMP-9 KO mice were devoid of multilayered plaques
(Figure 7, C and G) and exhibited a phenotype similar to
lenses without the TGF-b1 transgene (Figure 7, A and E),
exhibiting the characteristic monolayer of lens epithelial
cells. The remaining 25% of TGF-b1/MMP-9 KO mice
developed focal multilayered plaques (Figure 7, D and H).
All lenses were subjected to IHC for a-SMA to determine
whether they contained myoﬁbroblasts, indicative of EMT.
All of the lenses of TGF-b1/MMP-9 wild-type mice exhibi-
ted a-SMA reactivity in areas where focal opacities had
developed (Figure 7J). Similarly, plaques that developed in
the 25% of the TGF-b1/MMP-9 KO lenses also expressed a-
SMA (Figure 7L). Control lenses (Figure 7I) and the 75% of
the TGF-b1/MMP-9 KO lenses that did not exhibit ASC
formation (Figure 7K) were also devoid of a-SMA.Figure 5 E-cadherin protein levels in LEC explant lysates and condi-
tioned media. A: Representative Western blot reveals E-cadherin protein
(120 kDa) in MMP-9 KO LEC explant lysates compared with their wild-type
littermates. B: Densitometric analysis of Western blot in LEC explant lysates
indicate no signiﬁcant difference in total E-cadherin protein between MMP-
9 KO (n Z 8) and wild-type (n Z 5) LEC explants. Data were normalized
with b-tubulin control and are expressed as means  SEM. C: ELISA
measuring E-cadherin in conditioned media of untreated and 500 pg/mL of
TGF-betreated (for 48 hours) wild-type and MMP-9 KO LEC explants. In the
media, TGF-b treatment leads to an increase in E-cadherin protein in wild-
type explants when compared with untreated wild-type controls. Levels of
E-cadherin in the media of MMP-9 KO explants after TGF-b treatment are
signiﬁcantly different from wild-type TGF-betreated levels (P Z 0.019)
and comparable to all untreated explant levels. Data are expressed as
means  SEM (n Z 3 to 6). *P < 0.05.Discussion
Proteases, such as the MMPs, are known to play a role in
lens development and cataract formation. However, the
functional requirement of MMPs in mediating cataracto-
genesis has only recently been investigated, and much
attention has been focused on the ﬁbrotic cataract pheno-
types ASC and PCO. Clinically, ASC and PCO have been
associated with elevated levels of active TGF-b, and
experimental models for both of these cataracts have been
developed using active TGF-b as a stimulus.10,16 MMPs,
and in particular MMP-2 and MMP-9, have been found to
proteolytically cleave latent TGF-b.40,41 Thus, it is feasible
that MMPs act upstream in initiating TGF-b activation
during early wound healing events associated with ASC and2008PCO. However, it has also been clearly indicated that
MMPs play a role(s) in regulating the cellular changes that
occur subsequent to treatment with active TGF-b, including
LEC migration, capsular contraction, and the EMT of
LECs.16 For example, previous studies, using the excised rat
lens model, have found that the inhibition of the matrix-
degrading enzymes, MMP-2 and MMP-9, results in sup-
pression of (active) TGF-bemediated EMT and subsequent
ASC formation.23 The current study has extended this work
and addressed the individual requirement(s) of these two
MMPs in ASC formation by examining whether TGF-
bemediated ASC would form on a MMP-2 or MMP-9 KO
mouse background. Our results indicated that nearly all the
MMP-9 KO mice failed to elicit ASC plaque formation after
adenoviral gene transfer of active TGF-b1 to the anterior
chamber, in contrast to the MMP-2 KO mice, whichajp.amjpathol.org - The American Journal of Pathology
TGF-beInduced ASC-Resistant Miceexhibited ASC formation in all cases. The resistance to ASC
formation in the MMP-9 KO mice was also accompanied by
a lack of expression of the myoﬁbroblast marker a-SMA.
To further corroborate these ﬁndings, the MMP-9 KO mice
were bred onto a transgenic mouse background with lens-
speciﬁc overexpression of self-activating TGF-b1. These
ﬁndings further indicated a resistance to ASC formation in
the absence of MMP-9 because 75% of the TGF-b1 trans-
genic mice on the MMP-9 KO background did not develop
cataracts. Together these ﬁndings indicate that, of the two
gelatinases investigated, MMP-9 expression is most critical
in mediating TGF-beinduced ASC formation.
Both MMP-2 and MMP-9 expression have been detected
in the normal rat and mouse lens.23,42,43 However, a number
of studies have reported that although MMP-9 is constitu-
tively expressed in the lens, MMP-2 expression appears
after treatment with growth factors or during cataract for-
mation.44,45 Our studies using the ex vivo rat lens indicated
that, although MMP-9 secreted protein could be detected in
untreated lenses, MMP-2 levels could not and were only
apparent after treatment with TGF-b.23 Quantitative RT-
PCR analysis of ASC plaque cells from rat lenses further
revealed an early induction of MMP-9 mRNA after 2 days
of TGF-b treatment, whereas MMP-2 was found to be up-
regulated at the later 4-day time point.22 A similar, coordi-
nated expression pattern of MMP-9 and MMP-2 has also
been described in other model systems of ﬁbrosis. For
example, on ligation of the carotid artery and subsequent
remodeling, MMP-9 expression was found to be signiﬁ-
cantly elevated above controls, and induction in MMP-2
expression commenced after the peak of MMP-9 expres-
sion.27 Additional evidence suggests that MMP-9 may act
upstream of MMP-2 in EMT. Stimulation of human LECs
with human recombinant MMP-9 was found to result inFigure 6 Effects of TGF-b treatment on b-catenin localization in MMP-9 KO mo
(C andD) explants, b-catenin is predominantly localized at the cellular margins in a co
type LECs exhibit primarily cytosolic expression of b-catenin (E and F), in contrast t
staining of b-catenin at cell borders (G and H). All explants were mounted in mediu
The American Journal of Pathology - ajp.amjpathol.orginduction in expression of MMP-2, and this was correlated
with increased expression of the EMT marker a-SMA.22
Although there is no evidence that MMP-9 directly regu-
lates MMP-2 expression, there are indirect mechanisms by
which MMP-9 may inﬂuence MMP-2. For example, MMP-
14, which is known to induce MMP-2 in other systems,46
was found to be up-regulated in rat lenses 4 days after
TGF-b treatment and 2 days after MMP-9 induction.22
Thus, induction in MMP-9 expression was found to pre-
cede MMP-14 and, as such, may act as an intermediate for
regulating MMP-2 expression.
The two gelatinases, MMP-2 and MMP-9, are known to
have similar substrate speciﬁcities for matrix proteins47,48
and have been found to work in concert in disease. For
example, in an experimental laser model of choroidal neo-
vascularization, deﬁciency in both MMP-2 and MMP-9
resulted in increased incidence and severity of the disease
compared with absence in only one of the two MMPs.28
MMP-2 and MMP-9 have, however, been found to
possess different roles in the cleaving of nonmatrix sub-
strates. MMP-2 can cleave sites of ﬁbroblast growth factor
receptor 1 and monocyte chemoattractant protein 3, but
MMP-9 cannot.49,50 In addition, through its proteolytic ac-
tivity, MMP-2 has been found to release ﬁbroblast growth
factor 2 from the lens capsule, contributing to lens epithelial
cell survival.51 Our earlier data suggested that MMP-2 and/
or MMP-9 may facilitate EMT of LECs by acting on the
nonmatrix substrate E-cadherin. E-cadherin has been
recognized as a critical factor in maintaining the epithelial
cell state, and its disruption has been associated with the
initial stages of transition to a mesenchymal phenotype.52,53
Proteolytic cleavage of the N-terminal extracellular domain
of E-cadherin by MMPs, referred to as E-cadherin shedding,
results in the formation of an E-cadherin extracellularuse lens epithelial explants. In untreated wild-type (A and B) and MMP-9 KO
bblestone arrangement. With 500 pg/mL of TGF-b treatment for 48 hours, wild-
o TGF-betreated MMP-9 KO explants, which resembled controls with marginal
m with DAPI to co-localize the nuclei (blue). Scale barZ 100 mm.
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Korol et aldomain fragment with reported sizes ranging from 50 to 84
kDa, compared with the intact 120-kDa protein.54 Indeed, in
a previous study we detected a shed 72-kDa E-cadherin
fragment in the conditioned media of lenses treated with
TGF-b2 that was not detected in the media from untreated
lenses.23 Importantly, the appearance of the E-cadherin
fragment in the TGF-betreated rat lenses was attenuated by
co-treatment with an MMP-2/MMP-9especiﬁc inhibitor,
implicating these two MMPs in the shedding process. In the
current study, we used lens epithelial explants from MMP-2
and MMP-9 KO mice to further examine E-cadherin. Ex-
plants from both wild-type and MMP-2 KO mice, after
treatment with TGF-b, exhibited cell-cell detachment with a
distinct loss in E-cadherin together with predominantly
cytosolic b-catenin localization, an elongation in cell shape,
and increased expression of a-SMA. Interestingly, the
MMP-9 KO explants, without TGF-b treatment, exhibited
irregular localization of E-cadherin compared with their
wild-type explants, and in some cells it appeared reduced.
Despite this staining pattern, overall E-cadherin protein
levels in the lens explant lysates from MMP-9 KO mice
versus wild-type mice were found to be the same. InFigure 7 Lens epithelium of TGF-b1 transgenic and TGF-b1/MMP-9 KO mice at 1
immunostaining for a-SMA (IeL, green). Unlike control lenses (A and E; nZ 12), TG
formation exuding into the anterior chamber (B and F; nZ 10), with immunoreac
with control, I). In 75% of TGF-b1/MMP-9 KO mice, a protection from plaque format
whereas 25% of TGF-b1/MMP-9 KO mice did develop subcapsular plaques (D and H)
DAPI to co-localize the nuclei (blue). c, cornea; le, lens epithelium. Scale barZ 1
2010addition, the levels of E-cadherin protein shed into the
media from the explants after TGF-b treatment were found
to be signiﬁcantly lower in the MMP-9 KO explants
compared with wild-type explants. Thus, the TGF-
beinduced disruption or change in E-cadherin that is
observed in the wild-type (and MMP-2 KO) explant cells
does not occur in the MMP-9 KO explants, and corre-
spondingly the MMP-9 KO explants did not exhibit
TGF-beinduced EMT-like changes, including b-catenin
localization and a-SMA expression. It is not known why the
E-cadherin staining pattern would be altered in the MMP-9
KO LECs; however, a recent report found that astrocytes
from MMP-9 KO mice exhibited an altered actin cytoskel-
eton and perturbed cell migration.55 The actin cytoskeleton
is known to regulate E-cadherin localization and stability56;
thus, it is possible that MMP-9 KO LECs have an altered
cytoskeletal arrangement. Because our laboratory and others
have found that actin-mediated signaling is involved in the
EMT of LECs,38,57 it will be important to further investigate
how the loss of MMP-9 may have an effect.
Our ﬁndings also revealed that compared with the adeno-
viral delivery model, the TGF-b transgenic model had anto 3 months of age. Histologic sections were stained with H&E or subjected to
F-b1 transgenics at this time point exhibit reorganization of cells and plaque
tivity of a-SMA conﬁrming the presence of subcapsular plaques (J compared
ion was observed (C and G) with no immunoreactivity for a-SMA (K; nZ 14),
with a-SMA reactivity (L; nZ 5). All sections were mounted in medium with
00 mm. Original magniﬁcation: 20 (AeD); 40 (EeH).
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MMP-9 KO background (25% exhibited cataracts versus the
9% in the adenoviral delivery model). One possible explana-
tion for these ﬁndings may be related to the delivery mode of
active TGF-b. In the transgenic model, the TGF-b1 transgene
is continuously producing self-activating TGF-b1 protein
beginning at embryonic day 15 and continuing for the entire
life span of the mouse, whereas adenoviral delivery of TGF-b1
to the anterior chamber and lens is transient. Thus, the trans-
genic approach may deliver larger and long-term levels of
active TGF-b than that of the adenoviral method. Indeed,
different transgenic promoters, with different strengths, have
been found to result in variability in the severity of anterior
chamber and lens defects in mice.58,59 Thus, some variation
between models is apparent and likely dependent on the levels
of active TGF-b and length of exposure. Nonetheless, in both
the TGF-b transgenic and the AdTGF-b model, MMP-9
KO mice exhibited a resistance to ASC formation, whereas
MMP-2 KO mice did not. A small number of the MMP-9 KO
mice developed cataracts, indicating that alternate MMP-
9eindependent mechanisms can mediate TGF-beinduced
ASC formation. This is not surprising given the complex na-
ture of TGF-b signaling and numerous downstream pathways,
as well as the potential involvement of other MMP family
members that have also been implicated in regulating EMT.18
Why some mice of the same background developed ASC and
others did not is unknown. However, one possibility is that the
levels of active TGF-b among the mice tested in both in vivo
models may have varied, leading to the stimulation of alternate
signaling pathways.
A number of studies have implicated MMPs, in particular
MMP-2 and MMP-9, in the EMT of LECs and in mediating
ASC formation. However, their individual roles had yet to
be characterized. This study has found that MMP-9 but not
MMP-2 expression is necessary for TGF-bemediated lens
EMT and ASC formation. The mechanism(s) by which
MMP-9 deﬁciency results in resistance to TGF-beinduced
EMT in the lens and how this may involve actin cytoskel-
eton signaling will be important for future investigations.
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